Labcorp reported its first‑quarter 2026 results on April 30, 2026, posting adjusted earnings per share of $4.25—$0.13 above the consensus estimate of $4.12—and revenue of $3.54 billion, $0.03 billion above the $3.51 billion consensus. The earnings beat was driven by disciplined cost management and a favorable mix shift toward higher‑margin specialty tests, which helped the company maintain an adjusted operating margin of 14.4%, up 30 basis points from the 14.1 % reported a year earlier.
Revenue grew 5.8% year‑over‑year, powered by a 5.0% increase in Diagnostics segment sales and an 8.2% rise in the Biopharma Laboratory Services segment. The Diagnostics segment’s adjusted operating margin expanded to 16.6% from 16.3%, while the Biopharma segment’s margin improved to 15.5% from 14.8%, reflecting both pricing power and efficient cost control across the business.
Labcorp’s GAAP diluted earnings per share rose to $3.35 from $2.52 in Q1 2025, underscoring the company’s ability to translate higher revenue into stronger profitability. Free cash flow swung to $71 million, a turnaround from the $180 million cash use reported in the same quarter a year earlier, giving the company greater liquidity to fund strategic initiatives.
"Our focus on specialty testing and strategic acquisitions continues to drive significant value," said Chairman and CEO Adam Schechter. "We are off to a strong start in 2026, with continued momentum in both our Diagnostics and Central Laboratory businesses and significant progress across our strategic growth priorities." Schechter also noted that "our businesses remain strong due to our critical role in improving health and improving lives for people around the world." CFO Julia Wang added, "In the first quarter, enterprise revenue grew 5.8% and enterprise adjusted operating margin expanded more than 30 basis points to 14.4%. Adjusted EPS was $4.25 and we generated $71 million in free cash flow."
Labcorp raised its full‑year 2026 guidance, lifting the adjusted EPS range to $17.70–$18.35 (midpoint $18.03) and the enterprise revenue growth guidance to 5.0%–6.1%. The guidance increase signals management’s confidence that demand will remain robust and that cost discipline will continue to support margin expansion. The new outlook also reflects the company’s ongoing investment in specialty testing, AI‑driven platforms, and strategic acquisitions that are expected to drive long‑term growth.
The combination of a strong earnings beat, margin expansion, and a higher guidance outlook positions Labcorp favorably for the remainder of 2026. The company’s ability to generate positive free cash flow and maintain disciplined cost control while expanding its specialty testing portfolio suggests a resilient business model that can weather competitive pressures and regulatory changes. Investors will likely view the guidance raise as a positive signal of management’s confidence in sustained demand and operational execution.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.